1/24
05:09 am
kmda
Kamada (NASDAQ:KMDA) had its "buy (b-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Kamada (NASDAQ:KMDA) had its "buy (b-)" rating reaffirmed by analysts at
Weiss Ratings.
1/8
10:57 am
kmda
Kamada (NASDAQ:KMDA) had its "buy" rating reaffirmed by analysts at Benchmark Co..
Low
Report
Kamada (NASDAQ:KMDA) had its "buy" rating reaffirmed by analysts at Benchmark Co..
1/7
07:13 am
kmda
Kamada Provides 2026 Annual Guidance of $200 - $205 Million in Revenues and $50 - $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance [Yahoo! Finance]
Low
Report
Kamada Provides 2026 Annual Guidance of $200 - $205 Million in Revenues and $50 - $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance [Yahoo! Finance]
1/7
07:00 am
kmda
Kamada Provides 2026 Annual Guidance of $200 - $205 Million in Revenues and $50 - $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance
Medium
Report
Kamada Provides 2026 Annual Guidance of $200 - $205 Million in Revenues and $50 - $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance
12/18
07:00 am
kmda
Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender
Low
Report
Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender
12/9
07:01 am
kmda
Kamada (NASDAQ:KMDA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Kamada (NASDAQ:KMDA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/8
07:00 am
kmda
Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026
Medium
Report
Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026